Investigating how specific proteins are targeted for degradation in cells

Substrate targeting mechanism of a DesCEND pathway

NIH-funded research University of Connecticut Sch of Med/dnt · NIH-10797111

This study is looking at how a protein called FBXO31 works to find and break down other proteins in our cells, which could help us understand more about how proteins are controlled and lead to new treatments for patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Connecticut Sch of Med/dnt NIH-funded
Lab location1 site (Farmington, United States)
Project IDNIH-10797111 on NIH RePORTER

What this research studies

This research focuses on understanding the mechanisms by which a specific protein, FBXO31, identifies and interacts with its target substrates for degradation within a cellular pathway known as DesCEND. By utilizing an advanced automated system for high-throughput crystallization, the researchers aim to analyze the structural details of these protein-substrate interactions at both molecular and systems levels. This approach will help in identifying the specific characteristics that determine how proteins are recognized and processed in the cell. Patients may benefit from insights gained into protein regulation, which could inform future therapeutic strategies.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals with conditions linked to protein degradation disorders or those interested in the molecular mechanisms of cellular processes.

Not a fit: Patients with conditions unrelated to protein degradation or those not affected by cellular signaling pathways may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that target protein degradation pathways, potentially improving outcomes for patients with diseases related to protein misregulation.

How similar studies have performed: Other research has shown success in understanding protein degradation pathways, indicating that this approach has the potential for meaningful advancements.

Where this research is happening

Farmington, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.